Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis.
Angiogenesis, the induction of vessel growth is involved in numerous physiological and pathological processes. While the anti-tumor effect of angiogenesis inhibitors has been extensively investigated in malignant tumors, there is very little information on the effect of angiogenesis inhibitors on inflammation induced angiogenesis. In this report, we utilized a murine model of acute chemically induced cystitis to investigate the ability of three different angiogenesis inhibitors, angiostatin, endostatin and TNP-470, to inhibit the angiogenesis stimulated by this injury. We demonstrate herein, that prophylactic application of the angiogenesis inhibitors led to a significant reduction of each of the inflammatory parameters that were measured. We conclude that anti-angiogenic therapy with angiostatin, endostatin and TNP-470 inhibits inflammation associated angiogenesis induced in this model. We also propose that anti-angiogenic agents may serve as a valuable addition to a standard cyclophosphamid chemotherapy regimen to help reduce the chemotherapy-related side effects while potentially adding an anti-tumor effect.
Department of Urology, JW Goethe University, Frankfurt am Main, Germany. beecken@em.uni-frankfurt.de
Wolf-Dietrich
WD
Beecken
Tobias
T
Engl
Roman
R
Blaheta
Wassilios
W
Bentas
Eike-Gerd
EG
Achilles
Dietger
D
Jonas
Yuen
Y
Shing
Kevin
K
Camphausen
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D043168:Angiostatins / Q000494:pharmacology; D000818:Animals; D002199:Capillary Permeability; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D043169:Endostatins / Q000494:pharmacology; D007249:Inflammation / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D043169:Endostatins; D012717:Sesquiterpenes; D043168:Angiostatins; D003520:Cyclophosphamide; D000077609:O-(Chloroacetylcarbamoyl)fumagillol